Literature DB >> 11825972

Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo.

Sarah F Gee1, Sophie Joly, David R Soll, Jacques F G M Meis, Paul E Verweij, Itzhack Polacheck, Derek J Sullivan, David C Coleman.   

Abstract

The present study investigates further the population structure of Candida dubliniensis and its ability to exhibit microevolution. Using 98 isolates (including 80 oral isolates) from 94 patients in 15 countries, we confirmed the existence of two distinct populations within the species C. dubliniensis, designated Cd25 group I and Cd25 group II, respectively, on the basis of DNA fingerprints generated with the C. dubliniensis-specific probe Cd25. The majority of Cd25 group I isolates (48 of 71, 67.6%) were from human immunodeficiency virus (HIV)-infected individuals, whereas the majority of Cd25 group II isolates (19 of 27, 70.4%) were from HIV-negative individuals (P < or = 0.001). Nucleotide sequence analysis of the internal transcribed spacer (ITS) regions of the rRNA genes from 19 representative isolates revealed the presence of four separate genotypes. All of the Cd25 group I isolates tested belonged to genotype 1, while the Cd25 group II population was comprised of three distinct genotypes (genotypes 2 to 4), which corresponded to distinct clades within the Cd25 group II population. These findings were confirmed using genotype-specific PCR primers with 70 isolates. We also showed that C. dubliniensis can exhibit microevolution in vivo and in vitro as occurs in other yeast species. DNA fingerprinting using the C. dubliniensis probes Cd25, Cd24, and Cd1 and karyotype analysis of multiple oral isolates recovered from the same specimen from each of eight separate patients revealed microevolution in six of eight of the clonal populations. Similarly, sequential clonal isolates from various anatomical sites in two separate patients exhibited microevolution. Microevolution was also shown to occur when two clinical isolates susceptible to fluconazole were exposed to the drug in vitro. The epidemiological significance of the four C. dubliniensis genotypes and the ability of C. dubliniensis to undergo microevolution has yet to be established.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11825972      PMCID: PMC153410          DOI: 10.1128/JCM.40.2.556-574.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  58 in total

1.  Chlamydospore formation on Staib agar as a species-specific characteristic of Candida dubliniensis.

Authors:  P Staib; J Morschhäuser
Journal:  Mycoses       Date:  1999       Impact factor: 4.377

2.  Recovery of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Israel.

Authors:  I Polacheck; J Strahilevitz; D Sullivan; S Donnelly; I F Salkin; D C Coleman
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

3.  Rapid PCR test for discriminating between Candida albicans and Candida dubliniensis isolates using primers derived from the pH-regulated PHR1 and PHR2 genes of C. albicans.

Authors:  O Kurzai; W J Heinz; D J Sullivan; D C Coleman; M Frosch; F A Mühlschlegel
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

4.  Specific chromosome alterations in fluconazole-resistant mutants of Candida albicans.

Authors:  V Perepnikhatka; F J Fischer; M Niimi; R A Baker; R D Cannon; Y K Wang; F Sherman; E Rustchenko
Journal:  J Bacteriol       Date:  1999-07       Impact factor: 3.490

5.  Oral Candida dubliniensis as a clinically important species in HIV-seropositive patients in the United States.

Authors:  T F Meiller; M A Jabra-Rizk; A a Baqui; J I Kelley; V I Meeks; W G Merz; W A Falkler
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1999-11

6.  Rapid identification of Candida dubliniensis with commercial yeast identification systems.

Authors:  D H Pincus; D C Coleman; W R Pruitt; A A Padhye; I F Salkin; M Geimer; A Bassel; D J Sullivan; M Clarke; V Hearn
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

7.  Development and characterization of complex DNA fingerprinting probes for the infectious yeast Candida dubliniensis.

Authors:  S Joly; C Pujol; M Rysz; K Vargas; D R Soll
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

8.  Towards understanding the evolution of the human commensal yeast Candida albicans.

Authors:  Timothy J Lott; Brian P Holloway; David A Logan; Ruth Fundyga; Jonathan Arnold
Journal:  Microbiology       Date:  1999-05       Impact factor: 2.777

9.  Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences.

Authors:  Samantha M Donnelly; Derek J Sullivan; Diarmuid B Shanley; David C Coleman
Journal:  Microbiology       Date:  1999-08       Impact factor: 2.777

10.  Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation.

Authors:  J F Meis; M Ruhnke; B E De Pauw; F C Odds; W Siegert; P E Verweij
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

View more
  33 in total

1.  Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.

Authors:  Bettina C Fries; Emily Cook; Xiabo Wang; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Prevalence of Candida dubliniensis fungemia in Argentina: identification by a novel multiplex PCR and comparison of different phenotypic methods.

Authors:  Maria Eugenia Bosco-Borgeat; Constanza Giselle Taverna; Susana Cordoba; Maria Guillermina Isla; Omar Alejandro Murisengo; Wanda Szusz; Walter Vivot; Graciela Davel
Journal:  Mycopathologia       Date:  2011-07-13       Impact factor: 2.574

3.  Use of amplified fragment length polymorphism analysis to identify medically important Candida spp., including C. dubliniensis.

Authors:  A Borst; B Theelen; E Reinders; T Boekhout; A C Fluit; P H M Savelkoul
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

4.  Novel 5-flucytosine-resistant clade of Candida dubliniensis from Saudi Arabia and Egypt identified by Cd25 fingerprinting.

Authors:  Asmaa Al Mosaid; Derek J Sullivan; Itzhack Polacheck; Faisal A Shaheen; Osama Soliman; Saleh Al Hedaithy; Sahar Al Thawad; Motaz Kabadaya; David C Coleman
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  Extensive chromosome rearrangements distinguish the karyotype of the hypovirulent species Candida dubliniensis from the virulent Candida albicans.

Authors:  B B Magee; Melissa D Sanchez; David Saunders; David Harris; M Berriman; P T Magee
Journal:  Fungal Genet Biol       Date:  2007-07-20       Impact factor: 3.495

6.  High-throughput identification and quantification of Candida species using high resolution derivative melt analysis of panfungal amplicons.

Authors:  Tasneem Mandviwala; Rupali Shinde; Apoorv Kalra; Jack D Sobel; Robert A Akins
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

7.  Racial distribution of Candida dubliniensis colonization among South Africans.

Authors:  Elaine Blignaut; Claude Pujol; Sophie Joly; David R Soll
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

8.  Isolation of Candida dubliniensis in an aboriginal community in Ontario, Canada.

Authors:  Laura Montour; Rovena Tey; Jianping Xu
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  Environmental source of Candida dubliniensis.

Authors:  Miles A Nunn; Stefanie M Schäefer; Michael A Petrou; Jillian R M Brown
Journal:  Emerg Infect Dis       Date:  2007-05       Impact factor: 6.883

10.  Genetic differences between avian and human isolates of Candida dubliniensis.

Authors:  Brenda A McManus; Derek J Sullivan; Gary P Moran; Christophe d'Enfert; Marie Elisabeth Bougnoux; Miles A Nunn; David C Coleman
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.